MapLight Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 26, 2025, details the Initial Public Offering (IPO) and related corporate actions of MapLight Therapeutics, Inc. The Company is a Delaware corporation with its principal executive offices in Redwood City, California. The report covers events occurring between October 26 and October 29, 2025, including the execution of underwriting agreements, the closing of the IPO, and the adoption of amended and restated governance documents.
Key Financial Metrics and Capital Raised
- Total Gross Proceeds: $296.3 million (combined from IPO and Concurrent Private Placement).
- IPO Shares Sold: 14,750,000 shares of Common Stock at $17.00 per share.
- Over-Allotment Option: Underwriters exercised in full their option to purchase an additional 2,212,500 shares at $17.00 per share.
- Concurrent Private Placement: 467,707 shares sold to affiliates of Goldman Sachs & Co. LLC at $17.00 per share.
- Placement Agent Fee: 7.0% of the total purchase price for the Concurrent Private Placement.
- Net Proceeds: The filing states gross proceeds before deducting underwriting discounts, commissions, and offering expenses; net proceeds are not explicitly quantified in this text.
Material Changes and Corporate Actions
- Public Listing: Common Stock (Symbol: MPLT) began trading on The Nasdaq Stock Market LLC following the IPO closing on October 28, 2025.
- Governance Amendments: The Company filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws, effective upon the closing of the IPO.
- Unregistered Sales: The Concurrent Private Placement shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 and are not registered.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, revenue projections, or specific risk factors beyond standard securities law disclosures regarding the unregistered nature of the private placement shares. Management commentary is limited to the confirmation of the transaction closing and the execution of the underwriting and share purchase agreements. The Company is designated as an emerging growth company.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($296.3 million) are listed.
- Confirm the lock-up period terms for the Concurrent Private Placement shares sold to Goldman Sachs affiliates, as these are unregistered securities.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for any specific anti-takeover provisions or director liability limitations.
- Check subsequent filings for the actual cash balance and burn rate post-IPO, as this 8-K does not provide a balance sheet or cash flow statement.